Vyriad Secures $25M to Advance In Vivo CAR-T VV169
Rochester, Minnesota | December 23, 2025 — Vyriad, Inc., a clinical-stage biotechnology company developing targeted genetic therapies, announced the...
AI in Healthcare Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Rochester, Minnesota | December 23, 2025 — Vyriad, Inc., a clinical-stage biotechnology company developing targeted genetic therapies, announced the...
PALO ALTO, CA., June 30, 2025 — BridgeBio Pharma, Inc. (Nasdaq: BBIO), the biopharmaceutical company dedicated to developing transformative...
Lake Worth, FL. & New York, August 23, 2025 – Thomas H. Lee Partners (THL) has entered into a...
August 8, 2025 — London, UK. BioNTech SE has reached an agreement with CureVac to receive a non-exclusive license...
NORTH CHICAGO, IL. and SAN DIEGO, CA, August 19, 2025 – AbbVie (NYSE: ABBV) and Capstan Therapeutics, Inc. (“Capstan”),...
